Long-term L-NAME treatment potentiates the blood-brain barrier disruption during pentylenetetrazole-induced seizures in rats

Long-term L-NAME treatment potentiates the blood-brain barrier disruption during pentylenetetrazole-induced seizures in rats
复制标题

DOI:
10.1016/j.lfs.2005.12.034
复制
发表时间:
2006-05-30
期刊:
影响因子:
6.1
通讯作者:
Kucuk, Mutlu
Kucuk, Mutlu
中科院分区:
医学2区
文献类型:
--
作者:
Kalayci, Rivaze;Kaya, Mehmet;Kucuk, Mutlu

文献摘要

被引文献

相似文献

我们研究了戊四氮诱导的癫痫发作所引起的血脑屏障破坏的严重程度是否通过长期抑制大鼠一氧化氮合酶来改变。给大鼠饮用水中的一氧化氮合酶抑制剂N-ω-硝基-L-精氨酸甲酯(L-NAME)4周,然后用戊四唑诱导癫痫发作。使用伊文思蓝染料外渗研究血脑屏障的损伤。L-NAME治疗组大鼠血清NO浓度明显降低(P < 0.01)。L-NAME和/或戊四氮处理组动物收缩压升高(P < 0.01)。注射戊四唑后,L-NAME引起死亡率增加,导致动物在癫痫发作后约15分钟死亡。L-NAME处理的戊四氮致痫大鼠大脑皮质、间脑和小脑的伊文思蓝渗出量显著高于对照组(P < 0.01)。这里提出的数据表明,癫痫发作引起的血脑屏障破坏的程度在长期一氧化氮缺乏症中更为明显。(c)2005年爱思唯尔公司All rights reserved.
We investigated whether the severity of blood-brain barrier disruption caused by pentylenetetrazole-induced seizures is modified by long-term nitric oxide synthase inhibition in rats. Rats were given N-omega-nitro-L-arginine methyl ester (L-NAME), a nitric oxide synthase inhibitor, in drinking water for 4 weeks, and then treated with pentylenetetrazole to induce seizures. Damage to the blood-brain barrier was investigated using Evans blue dye extravasation. Serum nitric oxide concentration was decreased in L-NAME-treated rats (P < 0.01). L-NAME and/or pentylenetetrazole treatments elevated systolic blood pressure of animals (P < 0.01). L-NAME caused an increase in the mortality rate after pentylenetetrazole injection leading to the death of animals at about 15 min after the onset of the seizure. Pentylenetetrazole-induced seizures in rats treated with L-NAME caused a significant increase in Evans blue dye extravasation into cerebral cortex, diencephalon and cerebellum, as compared with seizures evoked by pentylenetetrazole injection to L-NAME-untreated rats (P < 0.01). Data presented here suggest that the degree of blood-brain barrier disruption induced by seizures is more pronounced in long-term nitric oxide deficiency. (c) 2005 Elsevier Inc. All rights reserved.